Drug Shortage Report for TEVA-SPIRONOLACTONE

Last updated on 2022-12-15 History
Report ID 167255
Drug Identification Number 00613223
Brand name TEVA-SPIRONOLACTONE
Common or Proper name SPIRONOLACTONE
Company Name TEVA CANADA LIMITED
Market Status MARKETED
Active Ingredient(s) SPIRONOLACTONE
Strength(s) 100MG
Dosage form(s) TABLET
Route of administration ORAL ORAL
Packaging size 100
ATC code C03DA
ATC description POTASSIUM-SPARING AGENTS
Reason for shortage Disruption of the manufacture of the drug.
Anticipated start date
Actual start date 2022-08-18
Estimated end date 2022-12-20
Actual end date 2022-12-14
Shortage status Resolved
Updated date 2022-12-15
Company comments
Health Canada comments
Tier 3 Status No
Contact Address 30 NOVOPHARM COURT
TORONTO, ONTARIO
CANADA M1B 2K9
Company contact information

Version History

Click on "Compare" below to view the full report history and compare to other versions.

Version Number Date Updated Language
v13 2022-12-15 French Compare
v12 2022-12-15 English Compare
v11 2022-12-01 French Compare
v10 2022-12-01 English Compare
v9 2022-10-28 French Compare
v8 2022-10-28 English Compare
v7 2022-09-22 French Compare
v6 2022-09-22 English Compare
v5 2022-09-07 French Compare
v4 2022-09-07 English Compare
v3 2022-08-19 English Compare
v2 2022-08-18 French Compare
v1 2022-08-18 English Compare

Showing 1 to 13 of 13